Verve Therapeutics (NASDAQ:VERV) Upgraded to "Overweight" at Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of Verve Therapeutics (NASDAQ:VERV - Free Report) from a neutral rating to an overweight rating in a report issued on Tuesday, MarketBeat Ratings reports.

Several other equities analysts have also issued reports on the company. Guggenheim reiterated a "buy" rating on shares of Verve Therapeutics in a research note on Tuesday, March 25th. Canaccord Genuity Group raised their price target on shares of Verve Therapeutics from $32.00 to $39.00 and gave the company a "buy" rating in a research note on Tuesday, April 15th. Royal Bank of Canada reduced their price objective on shares of Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating on the stock in a research note on Tuesday, March 4th. HC Wainwright lifted their price objective on Verve Therapeutics from $15.00 to $25.00 and gave the stock a "buy" rating in a research note on Monday, April 14th. Finally, William Blair reaffirmed an "outperform" rating on shares of Verve Therapeutics in a research report on Friday, February 21st. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $25.75.

Verve Therapeutics Stock Up 1.8 %

Shares of NASDAQ:VERV traded up $0.08 during trading on Tuesday, reaching $4.59. 2,590,118 shares of the company traded hands, compared to its average volume of 1,710,185. Verve Therapeutics has a 52 week low of $2.86 and a 52 week high of $9.31. The firm has a market capitalization of $407.57 million, a PE ratio of -1.87 and a beta of 1.86. The company's 50 day moving average is $5.63 and its two-hundred day moving average is $5.92.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.58) earnings per share for the quarter, topping analysts' consensus estimates of ($0.72) by $0.14. The company had revenue of $13.08 million during the quarter, compared to the consensus estimate of $3.94 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. As a group, research analysts anticipate that Verve Therapeutics will post -2.49 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in VERV. GAMMA Investing LLC raised its stake in shares of Verve Therapeutics by 189.7% in the fourth quarter. GAMMA Investing LLC now owns 6,054 shares of the company's stock worth $34,000 after purchasing an additional 3,964 shares during the last quarter. KFG Wealth Management LLC purchased a new stake in Verve Therapeutics in the first quarter worth $46,000. IFP Advisors Inc raised its stake in Verve Therapeutics by 823,700.0% in the 4th quarter. IFP Advisors Inc now owns 8,238 shares of the company's stock valued at $47,000 after acquiring an additional 8,237 shares during the period. BNP Paribas Financial Markets purchased a new stake in shares of Verve Therapeutics during the 4th quarter valued at approximately $50,000. Finally, Impact Partnership Wealth LLC bought a new position in shares of Verve Therapeutics in the fourth quarter worth $70,000. Institutional investors own 97.11% of the company's stock.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.